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LINEAberrant DNA methylation is induced at speciﬁc promoter CpG islands (CGIs) in contrast with mutations. The
speciﬁcity is inﬂuenced by genome architecture and epigenetic factors, but their relationship is still unknown.
In this study, we isolated promoter CGIs susceptible and resistant to aberrant methylation induction during
prostate and breast carcinogenesis. The effect of genome architecture was more evident for promoter CGIs
susceptible in both of the two tissues than for promoter CGIs susceptible only in one tissue. Multivariate
analysis of promoter CGIs with tissue-nonspeciﬁc susceptibility showed that genome architecture, namely a
remote location from SINE (OR=5.98; 95% CI=2.33–15.34) and from LINE (OR=2.08; 95% CI=1.03–4.21),
was associated with increased susceptibility, independent of epigenetic factors such as the presence of RNA
polymerase II (OR=0.09; 95% CI=0.02–0.48) and H3K27me3 (OR=3.28; 95% CI=1.17–9.21). These results
showed that methylation susceptibility of promoter CGIs is determined both by genome architecture and
epigenetic factors, independently.rase II; NFR, nucleosome free
H3K27me3, trimethylation of
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Epigenetic modiﬁcations play critical roles in diverse biological
processes such as transcription and DNA repair [1–3], and their
alterations are involved in human disorders, including cancers [4,5]. In
particular, aberrant DNA methylation of promoter CpG islands (CGIs),
especially of nucleosome-free regions (NFRs), causes silencing of
multiple genes, including tumor suppressor genes [6–8], and is deeply
involved in human carcinogenesis [4,5]. Contrary to mutations,
aberrant methylation is known to be induced at speciﬁc genes by
speciﬁc inducers [9,10]. The presence of such speciﬁcity was con-
vincingly shown bymethylation analyses of polyclonal tissues, such as
gastric mucosae of people with Helicobacter pylori infection [9] and
esophageal mucosae of patients with smoking history [10]. Subse-
quently, by methylated DNA immunoprecipitation (MeDIP) and
human CGI microarray analyses of multiple cancer cell lines and
their normal counterpart cells, we showed that some promoter CGIs
are susceptible across tissues (tissue-nonspeciﬁcally) to methylation
induction while others are tissue-speciﬁcally susceptible [11].As for the mechanisms of the target gene speciﬁcity, transcription
levels and epigenetic factors have been known to be involved.
Initially, involvement of low transcription levels was implicated by
analysis of speciﬁc genes [12–15] and then demonstrated by a
genome-wide analysis [11]. The premarking of DNA methylation-
susceptible genes by trimethylation of histone H3 lysine27
(H3K27me3), a DNA methylation-independent repressive modiﬁca-
tion [16], was initially implicated by analysis of a limited number of
genes [17,18], and then demonstrated by genome-wide analyses
[11,19,20]. We recently demonstrated that the presence of RNA
polymerase II (Pol II) protects promoter CGIs from becoming meth-
ylated, even if their downstream genes are not actively transcribed
(stalled Pol II) [11,21]. Some transcription factors, such as NRF1, Sp1,
and YY1, have also been shown to protect promoter CGIs from be-
coming methylated [22].
In contrast to epigenetic factors, only a limited number of reports
are available for the involvement of genome architecture in DNA
methylation susceptibility of promoter CGIs. A pioneering work by
Feltus et al. identiﬁed genomic motives associated with methylation-
susceptible and -resistant CGIs, and showed that motives associated
with methylation-resistant genes tended to be associated with Alu,
the major human short interspersed elements (SINE), and other
repetitive sequences [23]. A recent work by Estécio et al. showed that,
compared with methylation-resistant genes, methylation-susceptible
genes have a lower frequency of SINE and long interspersed element
(LINE) retrotransposons near their transcription start sites (TSSs)
[24]. However, it is still unknown whether the effects of genome
architecture are independent from those of epigenetic factors,
Fig. 1. Classiﬁcation of promoter CGIs into those susceptible and resistant to aberrant
DNA methylation induction, and classiﬁcation of susceptible promoter CGIs into
those with tissue-nonspeciﬁc and -speciﬁc susceptibility. (A) Classiﬁcation of
promoter CGIs into those susceptible and resistant to aberrant methylation
induction. Promoter CGIs unmethylated (white) in both of the two normal cells
and methylated (black) in one to ﬁve cancer cell lines were classiﬁed into Groups S1
to S5. Those unmethylated in both of the two normal cells and also in all cancer cell
lines were classiﬁed into Group R. Those unmethylated in both of the two normal
cells and intermediately methylated (gray) at least in one of the ﬁve cancer cell lines
were classiﬁed into the intermediate group (Int). Promoter CGIs in Groups S2 to S5
and in Group R were considered to be susceptible and resistant, respectively, to
aberrant methylation induction. In the prostate, a total of 262 and 5194 promoter
CGIs were susceptible and resistant, respectively. In the mammary glands, a total of
280 and 5352 promoter CGIs were susceptible and resistant, respectively. (B)
Classiﬁcation of susceptible promoter CGIs into promoter CGIs with tissue-
nonspeciﬁc and -speciﬁc susceptibility. A total of 154 promoter CGIs were susceptible
both in the prostate and mammary glands (black), and 62 and 55 were susceptible
only in the prostate and mammary glands, respectively (gray).
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nonspeciﬁcally and tissue-speciﬁcally susceptible promoter CGIs.
In this study, we will ﬁrst conﬁrm that DNA methylation-
susceptible promoter CGIs were located more remotely from SINE
and LINE than resistant promoter CGIs. We will then show i) that the
effect of genome architecture was more evident for tissue-nonspeciﬁc
susceptibility than for tissue-speciﬁc susceptibility, and ii) that the
effect of genome architecture was independent from those of epige-
netic factors such as the presence of Pol II and H3K27me3.
2. Results
2.1. Promoter CGIs are classiﬁed into those susceptible and resistant to
aberrant DNA methylation induction
Susceptibility of promoter CGIs of genes to aberrant DNA meth-
ylation induction was determined based on methylation statuses in
two normal cells and ﬁve cancer cell lines in the prostate and mam-
mary glands. Promoter CGIs unmethylated (Me value, 0–0.4) in both
of the two normal cells and methylated (Me value, 0.6–1.0) in one to
ﬁve of the ﬁve cancer cell lines were classiﬁed into Groups S1 to S5,
respectively. Those unmethylated in both of the two normal cells and
also in all of the ﬁve cancer cell lines were classiﬁed into Group R
(Fig. 1A). Those unmethylated in both of the two normal cells and
intermediately methylated (Me value, 0.4–0.6) at least in one of the
ﬁve cancer cell lines were classiﬁed into the intermediate group
(Group Int). Promoter CGIs in Groups S2 to S5 were considered to be
susceptible, and those in Group R were considered to be resistant. A
total of 262 and 280 promoter CGIs were classiﬁed as susceptible in
the prostate and mammary glands, respectively, and 5194 and 5352
promoter CGIs, respectively, were as resistant. House-keeping genes
with abundant expression and promoter CGIs, such as GAPDH and
ACTB, belonged to the resistant genes.
2.2. Promoter CGIs susceptible to aberrant DNA methylation induction
are located remotely from SINE and LINE
The effect of genome architecture on DNA methylation susceptibil-
ity was analyzed using the distance between a promoter CGI and
SINE (or LINE) (Fig. 2A). In the prostate, susceptible promoter CGIs
(n=262) were located more remotely from SINE (Pb1×10−5) and
LINE (Pb1×10−5) than resistant ones (n=5194) (Figs. 2B and D). The
same difference was observed in themammary glands (Pb1×10−5 for
SINE and LINE) (Figs. 2C and E). These results showed that promoter
CGIs located remotely from SINE and LINE are more susceptible to
aberrant methylation induction than those located closely to them.
2.3. Promoter CGIs with tissue-nonspeciﬁc susceptibility are located
more distant from SINE and LINE than promoter CGIs with tissue-speciﬁc
susceptibility
One hundred and ﬁfty-four promoter CGIs were susceptible both in
the prostate and mammary glands (tissue-nonspeciﬁc susceptibility).
On the other hand, 62 promoter CGIs were susceptible only in the
prostate and resistant or intermediate in the mammary glands, and 55
were susceptible only in the mammary glands and resistant or
intermediate in the prostate (tissue-speciﬁc susceptibility) (Fig. 1B).
The promoter CGIs with tissue-nonspeciﬁc susceptibility were located
signiﬁcantlymore remotely from SINE (P=0.005) and LINE (P=0.026)
than promoter CGIs with tissue-speciﬁc susceptibility in the pros-
tate (Fig. 3A). The same tendency was observed in the mammary
glands (Fig. 3B), but the differencewasnot statistically signiﬁcant. These
results indicated that the promoting effect of the remote location from
SINE and LINE on aberrantmethylation induction, or protective effect of
the close location, is more evident for tissue-nonspeciﬁc susceptibility
than for tissue-speciﬁc susceptibility.2.4. Effects of genome architecture are independent from those of
epigenetic factors
Epigenetic factors, such as the presence of Pol II and H3K27me3,
are known to be involved in the target gene speciﬁcity of aberrant
DNA methylation induction [11]. To evaluate whether the effect of
genome architecture is independent from those of epigenetic factors,
multivariate logistic regression analysis was performed. In the pros-
tate (Table 1), a remote location from SINE [Multivariate-adjusted
odds ratio (OR)=5.98; 95% conﬁdence interval (CI)=2.33–15.34]
Fig. 2. The effect of remote location from SINE and LINE on aberrant DNA methylation induction during carcinogenesis. (A) The deﬁnition of the distance from SINE (or LINE) to the
promoter CGI of a gene. The distance from the proximal edge of SINE (or LINE) to the center of the probe (45 to 60 bp in length) nearest to the TSS was deﬁned as the distance from
SINE (or LINE) to the promoter CGI of a gene. NFR, nucleosome free region. (B) and (C) the distances from SINE (or LINE) to all, resistant, and susceptible promoter CGIs in the
prostate (B) and mammary glands (C). The boxes represent the 75th and 25th percentiles, and the line in the box represents the 50th percentile (the median). Whiskers represent
the maximum data within [75th percentile+1.5×(75th percentile−25th percentile)] and the minimum data within [25th percentile−1.5×(75th percentile−25th percentile)].
The data not included between the whiskers are indicated by dots. Susceptible promoter CGIs were located signiﬁcantly more remotely from SINE and LINE than resistant promoter
CGIs in both tissues. (D) and (E) The distribution of resistant and susceptible promoter CGIs from SINE and LINE in the prostate (D) and mammary glands (E). The fractions of
resistant (white) and susceptible (black) promoter CGIs in respective distances from SINE and LINE are shown.
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nonspeciﬁc susceptibility (Table 1, the highest quintiles). The
presence of Pol II (0.09; 0.02–0.48) and H3K27me3 (3.28; 1.17–
9.21) weakly retained independent protective and promoting effects,
respectively. Regarding the effects on tissue-speciﬁc susceptibility, aremote location from SINE and LINE did not retain the effects while
the promoting effect of H3K27me3 was evident (3.34; 1.02–10.94).
Also in the mammary glands (Table 2), a remote location retained
independent effects more clearly on tissue-nonspeciﬁc susceptibility
than on tissue-speciﬁc susceptibility.
Fig. 3. The effect of remote location from SINE and LINE on tissue-nonspeciﬁc and
tissue-speciﬁc susceptibility. Distance from SINE and LINE to all, resistant, tissue-
speciﬁcally susceptible, and tissue-nonspeciﬁcally susceptible promoter CGIs in the
prostate (A) and mammary glands (B). For the box plots, refer to the legend of Fig. 2B.
Tissue-nonspeciﬁcally susceptible promoter CGIs were located signiﬁcantly more
remotely from SINE and LINE than tissue-speciﬁcally susceptible promoter CGIs in the
prostate.
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have different characteristics
To reveal the characteristics of promoter CGIs whose susceptibility
was inﬂuenced mainly by genome architecture and those inﬂuenced
by epigenetic factors, gene ontology analysis of these promoter CGIs
was conducted. As promoter CGIs whose susceptibility was inﬂuenced
mainly by genome architecture, those located remotely from both
SINE (N2.5 kb) and LINE (N5.5 kb) and had high Pol II and low
H3K27me3 in normal cells were selected. As promoter CGIs whose
susceptibility was inﬂuenced mainly by epigenetic factors, promoterTable 1
The association between the distance from SINE, from LINE, or epigenetic factors and DNA
Lowest quintile 2nd quintile
Tissue-nonspeciﬁc susceptibility
The distance from SINE 1 3.28 (1.18–9.13)
The distance from LINE 1 1.12 (0.51–2.47)
Transcription 1 0.86 (0.55–1.36)
H3Ac 1 0.73 (0.41–1.30)
H3K4me3 1 1.19 (0.70–2.03)
Pol II 1 0.58 (0.34–1.02)
H3K9me3 1 1.74 (0.84–3.60)
H3K27me3 1 1.38 (0.47–4.10)
Tissue-speciﬁc susceptibility
The distance from SINE 1 1.25 (0.46–3.40)
The distance from LINE 1 0.33 (0.12–0.93)
Transcription 1 0.85 (0.42–1.73)
H3Ac 1 0.50 (0.19–1.30)
H3K4me3 1 1.43 (0.58–3.56)
Pol II 1 0.56 (0.22–1.45)
H3K9me3 1 0.98 (0.43–2.20)
H3K27me3 1 1.18 (0.35–3.95)
The association with tissue-nonspeciﬁc susceptibility and tissue-speciﬁc susceptibility was a
CI) for a CGI in a quintile to become methylated compared with a CGI in a reference quintile (
the variables listed. Signiﬁcant ORs are shown in bold.CGIs located closely to both SINE (b1.0 kb) and LINE (b1.5 kb) and
had low Pol II and high H3K27me3 in normal cells were selected.
In the prostate, among genes whose susceptibility was inﬂuenced
mainly by genome architecture, biological processes involved in
early developmental processes such as organ morphogenesis and
anterior/posterior pattern formation were enriched. Among genes
whose susceptibility was inﬂuenced mainly by epigenetic factors,
biological processes involved in basic cellular processes in speciﬁc
cell types such as neurotransmitter transport and amine transport
were enriched (Table 3). A similar result was also observed in the
mammary glands.3. Discussion
In this study, we conﬁrmed that a remote location from SINE and
LINE is associated with susceptibility of promoter CGIs to become
aberrantly methylated during carcinogenesis. Further, we showed
that the effect of genome architecture was more evident for tissue-
nonspeciﬁc susceptibility than for tissue-speciﬁc susceptibility, and
independent from those of epigenetic factors such as the presence of
Pol II and H3K27me3.
The protective effect of the close location to SINE and LINE can be
explained by the establishment of active chromatin. Some repetitive
sequences are known to be bound by transcription factors, and form
active chromatin that eventually protects CGIs from aberrant DNA
methylation induction. For example, SINE is known to contain binding
sites of YY1 transcription factor [25], which is known to interact with
histone acetyltransferases such as CBP (encoded by CREBBP) and p300
(encoded by EP300) [26,27]. Surrounding regions of SINE bound by
YY1 are expected to be marked with active histone modiﬁcations.
Genes whose susceptibility was inﬂuenced mainly by genome
architecture had functions involved in early developmental processes.
Since genes involved in early developmental processes are considered
to be unnecessary in differentiated cells of most tissues, methyla-
tion susceptibility of these genes is likely to be determined solely
by genome architecture. In contrast, genes whose susceptibility was
inﬂuenced mainly by epigenetic factors had functions involved in
basic cellular processes in speciﬁc cell types. Since such genes are
utilized in speciﬁc tissues, it is expected that such genes have different
epigenetic modiﬁcations in various normal tissues, and that meth-
ylation susceptibility of such genes will be determined mainly by
epigenetic factors.methylation susceptibility in the prostate.
3rd quintile 4th quintile Highest quintile
2.61 (0.91–7.46) 5.17 (1.96–13.60) 5.98 (2.33–15.34)
1.58 (0.75–3.30) 1.58 (0.76–3.27) 2.08 (1.03–4.21)
0.39 (0.19–0.83) 0.60 (0.28–1.26) 0.28 (0.10–0.83)
0.53 (0.25–1.12) 0.67 (0.28–1.56) 1.04 (0.37–2.92)
0.76 (0.38–1.52) 1.04 (0.49–2.17) 0.80 (0.34–1.84)
0.23 (0.10–0.57) 0.42 (0.17–1.05) 0.09 (0.02–0.48)
1.53 (0.73–3.21) 1.57 (0.75–3.28) 1.15 (0.54–2.47)
1.05 (0.35–3.20) 0.60 (0.18–1.99) 3.28 (1.17–9.21)
1.07 (0.38–2.99) 1.49 (0.57–3.87) 1.87 (0.75–4.68)
0.53 (0.22–1.27) 0.74 (0.34–1.65) 0.84 (0.39–1.83)
0.44 (0.17–1.16) 0.51 (0.19–1.39) 0.79 (0.32–1.98)
0.48 (0.16–1.44) 0.72 (0.24–2.15) 1.26 (0.38–4.20)
1.74 (0.67–4.52) 1.29 (0.45–3.66) 1.73 (0.62–4.79)
0.96 (0.37–2.50) 0.32 (0.09–1.15) 0.38 (0.10–1.43)
0.49 (0.19–1.26) 0.37 (0.14–0.99) 0.35 (0.13–0.94)
2.35 (0.74–7.44) 3.45 (1.07–11.15) 3.34 (1.02–10.94)
nalyzed separately. Multivariate-adjusted odds ratio (OR) (95% conﬁdence interval; 95%
lowest quintile) was calculated by multivariate logistic regression analysis involving all
Table 2
The association between the distance from SINE, from LINE, or epigenetic factors and DNA methylation susceptibility in the mammary glands.
Lowest quintile 2nd quintile 3rd quintile 4th quintile Highest quintile
Tissue-nonspeciﬁc susceptibility
The distance from SINE 1 3.35 (1.21–9.30) 2.73 (0.96–7.79) 5.66 (2.16–14.81) 6.31 (2.46–16.17)
The distance from LINE 1 1.25 (0.57–2.73) 1.68 (0.80–3.50) 1.74 (0.84–3.57) 2.07 (1.02–4.18)
Transcription 1 0.54 (0.32–0.92) 0.30 (0.14–0.63) 0.31 (0.14–0.68) 0.25 (0.10–0.62)
H3Ac 1 0.76 (0.43–1.35) 0.52 (0.23–1.17) 1.05 (0.43–2.58) 2.25 (0.77–6.57)
H3K4me3 1 1.06 (0.64–1.78) 0.52 (0.24–1.13) 0.77 (0.34–1.74) 0.57 (0.22–1.44)
Pol II 1 0.64 (0.37–1.12) 0.63 (0.31–1.31) 0.22 (0.08–0.64) 0.19 (0.06–0.65)
H3K9me3 1 1.45 (0.82–2.57) 1.26 (0.69–2.30) 1.21 (0.65–2.25) 0.86 (0.44–1.68)
H3K27me3 1 0.45 (0.18–1.13) 0.62 (0.27–1.42) 0.56 (0.24–1.33) 2.00 (0.96–4.17)
Tissue-speciﬁc susceptibility
The distance from SINE 1 2.00 (0.49–8.08) 2.38 (0.61–9.33) 2.42 (0.64–9.17) 3.78 (1.07–13.31)
The distance from LINE 1 1.14 (0.30–4.29) 1.87 (0.56–6.17) 1.89 (0.58–6.20) 2.93 (0.95–8.99)
Transcription 1 0.32 (0.13–0.79) 0.14 (0.04–0.51) 0.19 (0.06–0.60) 0.12 (0.03–0.45)
H3Ac 1 1.01 (0.36–2.79) 1.35 (0.40–4.53) 1.44 (0.35–5.88) 1.91 (0.35–10.33)
H3K4me3 1 0.69 (0.28–1.68) 0.49 (0.16–1.51) 0.23 (0.06–0.93) 0.23 (0.05–1.08)
Pol II 1 1.08 (0.42–2.80) 0.80 (0.21–3.03) 2.25 (0.62–8.10) 1.86 (0.37–9.44)
H3K9me3 1 0.47 (0.17–1.28) 0.92 (0.39–2.19) 0.78 (0.31–1.96) 0.47 (0.16–1.38)
H3K27me3 1 1.57 (0.47–5.26) 1.35 (0.39–4.71) 1.22 (0.33–4.54) 2.02 (0.61–6.74)
Using the data in the mammary glands, multivariate analyses were performed as in Table 1. Signiﬁcant ORs are shown in bold.
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a tissue, two tissues, the prostate and mammary glands, were analyzed.
Despite the limited number of analyzed tissues, the stronger effect of
genomearchitecture on tissue-nonspeciﬁcally susceptible promoter CGIs
than on tissue-speciﬁcally susceptible promoter CGIs could be observed.
Nevertheless, the number of tissues analyzed was still small to isolate a
pure population of tissue-nonspeciﬁcally susceptible promoter CGIs. It is
expected that the stronger effect of genome architecture will become
more evident when a larger number of tissues are analyzed.
For identiﬁcation of DNA methylation-susceptible and -resistant
promoter CGIs, we analyzed methylation statuses of cancer cell lines.
It is known that cancer cell lines generally have a larger number of
methylated genes than primary tumors. However, it was observed
that, when a large number of primary tumors were analyzed, most
methylation found in cancer cell lines was present also in a minor
fraction of the primary tumors [28–30]. Therefore, it is considered that
methylation susceptibility observed in cancer cell lines reﬂects that in
primary tumors as a whole.
In conclusion, DNA methylation susceptibility of promoter
CGIs is determined by genome architecture and epigenetic factors,
independently.
4. Materials and methods
4.1. Cell lines
A normal prostatic epithelial cell line (RWPE1), prostate cancer
cell lines (PC3, LNCaP, 22Rv1, Du145, and MDA-PCa-2b), and breastTable 3
Functional annotation analysis of genes whose susceptibility was inﬂuenced by genome arc
Category Prostate
Term
Genes whose susceptibility was inﬂuenced by genome architecture Skeletal system mo
Organ morphogen
Anterior/posterior
Regionalization
Pattern speciﬁcatio
Genes whose susceptibility was inﬂuenced by epigenetic factors Neurotransmitter t
Response to extern
Amine transport
Transport
Regulation of body
Enrichment of speciﬁc biological processes in Gene Ontology criteria among genes whose su
mammary glands) or epigenetic factors (n=9 in the prostate; n=9 in the mammary gland
biological processes in each gene category are listed. The signiﬁcance (P value) of enrichmecancer cell lines (BT474, MCF7, MDA-MB-231, MDA-MB-468, and
ZR-75-1) were obtained from the American Type Culture Collection
(Rockville, MD). Normal human prostate epithelial cells (PrEC) were
obtained from Lonza (Walkersville, MD). Normal human mammary
epithelial cells (HMECs) were obtained from Cambrex (East Ruther-
ford, NJ). PrEC was maintained in PrEGM BulletKit (Lonza), BT474 and
MDA-MB-231 were maintained in RPMI1640, and other cells were
maintained as described previously [11].4.2. Analysis of DNA methylation
DNA methylation data of RWPE1, PC3, LNCaP, 22Rv1, Du145,
HMEC (lot. OF1330), MCF7, MDA-MB-468, and ZR-75-1 were
obtained in our previous study [11]. Methylation statuses of PrEC,
MDA-PCa-2b, HMEC (lot. 0000092969), BT474, and MDA-MB-231
were newly analyzed in this study as described previously [11,31].
DNA immunoprecipitated by antibody against 5-methylcytidine
(Diagnode, Liége, Belgium) was analyzed by human CGI microarray
(Agilent Technologies, Santa Clara, CA) that contained 27,800 CGIs,
9838 of which were located within 200 bp upstream from TSSs, and
thus in promoter regions. The methylation level of each probe was
evaluated usingMe values ranging from 0 (completely unmethylated)
to 1 (fully methylated) [31]. The methylation status of each gene was
deﬁned as unmethylated, intermediately methylated, and methylated
when the average of theMe value of probes within a NFR (deﬁned as a
region between a TSS and its 200 bp upstream) was 0–0.4, 0.4–0.6,
and 0.6–1.0, respectively [11]. Methylation data of PrEC, MDA-PCa-2b,hitecture or epigenetic factors.
Mammary glands
P value Term P value
rphogenesis 1.93E−06 Anterior/posterior pattern formation 3.79E−06
esis 2.52E−06 Regionalization 1.06E−05
pattern formation 3.79E−06 Pattern speciﬁcation process 2.64E−05
1.06E−05 Embryonic morphogenesis 4.01E−05
n process 2.64E−05 Organ development 2.29E−04
ransport 2.91E−02 Neurotransmitter transport 3.48E−02
al stimulus 3.67E−02 Amine transport 4.91E−02
4.11E−02
4.79E−02
ﬂuid levels 4.90E−02
sceptibility was inﬂuenced by genome architecture (n=6 in the prostate; n=5 in the
s) was analyzed by DAVID bioinformatics resources. The top ﬁve signiﬁcantly enriched
nt is shown.
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to the GEO database under accession no. GSE28284.
4.3. Determination of the distance from SINE (or LINE) to the promoter
CGI of a gene
The position information of SINE and LINEwas obtained fromUCSC
hg18 (NCBI Build 36.1, March 2006). The distance from the proximal
edge of SINE (or LINE) to the center of the probe (45 to 60 bp in
length) nearest the TSS located within a NFR was deﬁned as the
distance from SINE (or LINE) to the promoter CGI of a gene (Fig. 2A).
4.4. Analyses of transcription level, histone modiﬁcations, and Pol II
binding
Transcription levels, histone modiﬁcations, and Pol II binding in
normal cells, RWPE1 and HMEC (lot. OF1330), were obtained from
our previous study [11]. Transcription levels were analyzed using
the GeneChip Human Genome U133 Plus 2.0 microarray (Affymetrix,
Santa Clara, CA). Histone modiﬁcations and Pol II binding were
analyzed by chromatin immunoprecipitation combined with a human
CGI microarray. Histone modiﬁcations and the Pol II binding level of
each gene were evaluated by the average of Cy5/Cy3 (bound/input)
signal ratio of probes within NFR. Genes were classiﬁed into those
with high and low levels of H3K27me3 or Pol II binding when they
had signal ratios higher and lower, respectively, than the average
signal ratio of total probes.
4.5. Functional annotation analysis
Functional annotation analysis was performed by DAVID bioinfor-
matics resources [32,33]. The enrichment of genes in a biological
process (a Gene Ontology criterion) was analyzed by comparing a
fraction of genes with an ontology among genes whose susceptibility
was inﬂuenced by genome architecture (or by epigenetic factors)
with that among all the genes.
4.6. Multivariate analysis and statistical tests
Multivariate logistic regression analysis was conducted using
DNA methylation susceptibility as an outcome variable. The predictor
variables [transcription, acetylation of histone H3 (H3Ac), trimethyla-
tion of histone H3 lysine4 (H3K4me3), Pol II binding, trimethylation
of histone H3 lysine9 (H3K9me3), H3K27me3, the distance from SINE,
and that from LINE] were categorized into quintiles according to their
values [transcription levels, histone modiﬁcation levels and Pol II
binding levels in RWPE1 or HMEC (lot. OF1330), and the distance
from SINE (or LINE) to the promoter CGI] to create dummy variables.
OR and 95% CI of methylation susceptibility of genes in each quintile,
using the lowest quintile as a reference, were calculated, including all
predictor variables simultaneously in the model using SAS software,
ver. 9.1 (SAS Institute Inc, SAS/STAT 9.1 user's guide, SAS Institute Inc,
Cary, NC). These ORs show a probability for a gene in a quintile to
become methylated, relative to the lowest quintile, after controlling
the effect of all the other predictor variables included in the model.
95% CIs show the range into which the true OR falls with a chance of
95% or greater. The distances from SINE and LINE in different groups of
genes were compared by the Mann–Whitney U-test.
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